Literature DB >> 18339852

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Yunqing Li1, Fadila Guessous, Sherwin Kwon, Manish Kumar, Opeyemi Ibidapo, Lauren Fuller, Elizabeth Johnson, Bachchu Lal, Isa Hussaini, Yongde Bao, John Laterra, David Schiff, Roger Abounader.   

Abstract

We show, for the first time, that the tumor suppressor PTEN can have tumor-promoting properties. We show that PTEN acquires these unexpected properties by enhancing gain-of-function mutant p53 (mut-p53) protein levels. We find that PTEN restoration to cells harboring mut-p53 leads to induction of G(1)-S cell cycle progression and cell proliferation and to inhibition of cell death. Conversely, PTEN inhibition in cells expressing wild-type PTEN and mut-p53 leads to inhibition of cell proliferation and inhibition of in vivo tumor growth. We show the dependency of the tumor-promoting effects of PTEN on mut-p53 by showing that knockdown of mut-p53 expression inhibits or reverses the tumor-promoting effects of PTEN. Mechanistically, we show that PTEN expression enhances mut-p53 protein levels via inhibition of mut-p53 degradation by Mdm2 and possibly also via direct protein binding. These findings describe a novel function of PTEN and have important implications for experimental and therapeutic strategies that aim at manipulating PTEN or p53 in human tumors. They suggest that the mutational status of PTEN and p53 should be considered to achieve favorable therapeutic outcomes. The findings also provide an explanation for the low frequency of simultaneous mutations of PTEN and p53 in human cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339852      PMCID: PMC3813002          DOI: 10.1158/0008-5472.CAN-07-1963

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  PTEN and p53: who will get the upper hand?

Authors:  Lloyd C Trotman; Pier Paolo Pandolfi
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

2.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

3.  PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.

Authors:  Lindsey D Mayo; Jack E Dixon; Donald L Durden; Nickolas K Tonks; David B Donner
Journal:  J Biol Chem       Date:  2001-11-29       Impact factor: 5.157

4.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.

Authors:  Keisuke Kurose; Kristie Gilley; Satoshi Matsumoto; Peter H Watson; Xiao-Ping Zhou; Charis Eng
Journal:  Nat Genet       Date:  2002-10-15       Impact factor: 38.330

5.  PTEN/MMAC1 mutations correlate inversely with an altered p53 tumor suppressor gene in gynecologic tumors.

Authors:  Emmanuel O Soyoola; Roland A Pattillo
Journal:  Am J Obstet Gynecol       Date:  2003-04       Impact factor: 8.661

Review 6.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

Authors:  C Cadwell; G P Zambetti
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

7.  PTEN regulates Mdm2 expression through the P1 promoter.

Authors:  Chun-Ju Chang; Daniel J Freeman; Hong Wu
Journal:  J Biol Chem       Date:  2004-04-16       Impact factor: 5.157

8.  Genetic pathways to glioblastoma: a population-based study.

Authors:  Hiroko Ohgaki; Pierre Dessen; Benjamin Jourde; Sonja Horstmann; Tomofumi Nishikawa; Pier-Luigi Di Patre; Christoph Burkhard; Danielle Schüler; Nicole M Probst-Hensch; Paulo César Maiorka; Nathalie Baeza; Paola Pisani; Yasuhiro Yonekawa; M Gazi Yasargil; Urs M Lütolf; Paul Kleihues
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

9.  p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.

Authors:  Yinglin Wang; Shaojun Zhu; Timothy F Cloughesy; Linda M Liau; Paul S Mischel
Journal:  Oncogene       Date:  2004-02-12       Impact factor: 9.867

Review 10.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Authors:  Lindsey D Mayo; David B Donner
Journal:  Trends Biochem Sci       Date:  2002-09       Impact factor: 13.807

View more
  44 in total

1.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

2.  PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.

Authors:  Stacey L Thomas; Ridwan Alam; Nancy Lemke; Lonni R Schultz; Jorge A Gutiérrez; Sandra A Rempel
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

3.  Evolutionary pathways in BRCA1-associated breast tumors.

Authors:  Filipe C Martins; Subhajyoti De; Vanessa Almendro; Mithat Gönen; So Yeon Park; Joanne L Blum; William Herlihy; Gabrielle Ethington; Stuart J Schnitt; Nadine Tung; Judy E Garber; Katharina Fetten; Franziska Michor; Kornelia Polyak
Journal:  Cancer Discov       Date:  2012-04-10       Impact factor: 39.397

4.  MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway.

Authors:  Yanzhi Yang; Samantha Dodbele; Thomas Park; Rainer Glass; Krishna Bhat; Erik P Sulman; Ying Zhang; Roger Abounader
Journal:  J Neurooncol       Date:  2019-09-03       Impact factor: 4.130

5.  TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.

Authors:  Nagako Akeno; Alisa L Reece; Melissa Callahan; Ashley L Miller; Rebecca G Kim; Diana He; Adam Lane; Jonathan S Moulton; Kathryn A Wikenheiser-Brokamp
Journal:  Mol Cancer Ther       Date:  2017-08-28       Impact factor: 6.261

6.  PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression.

Authors:  Tushar B Deb; Robert J Barndt; Annie H Zuo; Surojeet Sengupta; Christine M Coticchia; Michael D Johnson
Journal:  Cell Cycle       Date:  2014-01-20       Impact factor: 4.534

7.  Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity.

Authors:  Jia-Jean Yiin; Bo Hu; Michael J Jarzynka; Haizhong Feng; Kui-Wei Liu; Jane Y Wu; Hsin-I Ma; Shi-Yuan Cheng
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

8.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

9.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Authors:  Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

Review 10.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.